Medical Innovation Exchange

Aclaris stock halves after phase 2a skin study misses goals

https://www.fiercebiotech.com/biotech/aclaris-stock-halves-after-phase-2a-skin-study-misses-goals

Leave a Comment

Your email address will not be published. Required fields are marked *

Leave the field below empty!